EFFECTS OF ISONIAZID (INH) ON THE BCG-INDUCED LOCAL IMMUNE-RESPONSE AFTER INTRAVESICAL BCG THERAPY FOR SUPERFICIAL BLADDER-CANCER

被引:18
|
作者
STASSAR, MJJG
VEGT, PDJ
STEERENBERG, PA
VANDERMEIJDEN, APM
MEIRING, HD
DESSENSKROON, M
GEERTZEN, HGM
DENOTTER, W
机构
[1] NATL INST PUBL HLTH & ENVIRONM PROTECT,PATHOL LAB,POB 1,3720 BA BILTHOVEN,NETHERLANDS
[2] RIJNLAND HOSP,DEPT UROL,2350 CC LEIDERDORP,NETHERLANDS
[3] BOSCH MED CTR,DEPT UROL,5211 NL SHERTOGENBOSCH,NETHERLANDS
[4] RIVM,ORGAN ANALYT CHEM LAB,3720 BA BILTHOVEN,NETHERLANDS
[5] RIVM,MICROBIOL LAB,3720 BA BILTHOVEN,NETHERLANDS
[6] NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,1006 AD AMSTERDAM,NETHERLANDS
[7] UNIV UTRECHT,DEPT FUNCT MORPHOL,3508 TD UTRECHT,NETHERLANDS
来源
UROLOGICAL RESEARCH | 1994年 / 22卷 / 03期
关键词
BCG IMMUNOTHERAPY; ISONIAZID; SUPERFICIAL BLADDER CANCER;
D O I
10.1007/BF00571847
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Because recent investigations showed that the use of isoniazid (INH) severely impaired the local immune reaction to intravesical bacillus Calmette-Guerin (BCG) in the bladder of guinea pigs, in this study the effect of INH in man has been investigated. Patients were treated with BCG with or without oral INH. The concentration of free INH in most urine samples of patients treated with BCG/INH was much higher (mean 38.0 +/- 60.9 mug INH/ml) than the minimal inhibitory concentration (MIC; 0.1 mug INH/ml), suggesting at least a bacteriostatic potential of the INH present. However, in vitro studies showed that these urinary concentrations of INH did not kill BCG organisms effectively, even at a concentration of 150 mug/ml for 24h. After the fifth and sixth BCG instillations a significant increase in the concentration of cytokines (IL2, IL6, IL8 and TNFa), IgG and IgA antibodies to BCG and the number of leukocytes in urine was observed. The leukocytes mainly consisted of granulocytes, besides monocytes/macrophages and, in lower amounts, T- and B- lymphocytes and natural killer (NK) cells. The absolute number of granulocytes and the concentration of IgG antibodies after BCG instillation were significantly suppressed by INH, whereas INH appeared to have no effect on the urinary cytokine and IgA antibody concentrations or the total number and phenotype of the leukocytes present. In conclusion, the results of this study indicate that INH does not impair the local immunological stimulation after BCG instillation in man as severely as was observed in the guinea pig and it may be expected that INH does not impair the antitumor efficacy of BCG.
引用
收藏
页码:177 / 184
页数:8
相关论文
共 50 条
  • [1] INTRAVESICAL BCG FOR SUPERFICIAL BLADDER-CANCER
    KRANE, RJ
    BABAYAN, RK
    BRITISH JOURNAL OF UROLOGY, 1988, 61 (01): : 85 - 86
  • [2] TREATMENT OF SUPERFICIAL BLADDER-CANCER WITH INTRAVESICAL BCG
    CAMACHO, F
    PINSKY, C
    KERR, D
    WHITMORE, W
    OETTGEN, H
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1980, 21 (MAR): : 359 - 359
  • [3] ROLE OF FIBRONECTIN IN INTRAVESICAL BCG THERAPY FOR SUPERFICIAL BLADDER-CANCER
    RATLIFF, TL
    KAVOUSSI, LR
    CATALONA, WJ
    JOURNAL OF UROLOGY, 1988, 139 (02): : 410 - 414
  • [4] Autophagy Controls BCG-Induced Trained Immunity and the Response to Intravesical BCG Therapy for Bladder Cancer
    Buffen, Kathrin
    Oosting, Marije
    Quintin, Jessica
    Ng, Aylwin
    Kleinnijenhuis, Johanneke
    Kumar, Vinod
    van de Vosse, Esther
    Wijmenga, Cisca
    van Crevel, Reinout
    Oosterwijk, Egbert
    Grotenhuis, Anne J.
    Vermeulen, Sita H.
    Kiemeney, Lambertus A.
    van de Veerdonk, Frank L.
    Chamilos, Georgios
    Xavier, Ramnik J.
    van der Meer, Jos W. M.
    Netea, Mihai G.
    Joosten, Leo A. B.
    PLOS PATHOGENS, 2014, 10 (10)
  • [5] ROLE OF THE IMMUNE-RESPONSE IN BCG FOR BLADDER-CANCER
    RATLIFF, TL
    EUROPEAN UROLOGY, 1992, 21 : 17 - 21
  • [6] INTRAVESICAL BCG THERAPY OF SUPERFICIAL BLADDER-CANCER - STUDY OF ADVERSE-EFFECTS
    GALVAN, L
    AYANI, I
    ARRIZABALAGA, MJ
    RODRIGUEZSASIAIN, JM
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 1994, 19 (02) : 101 - 104
  • [7] The effect of isoniazid on BCG-induced toxicity in patients with superficial bladder cancer
    Al Khalifa, M
    Elfving, P
    Månsson, W
    Colleen, S
    Hellsten, S
    Duchek, M
    Nyberg, G
    Callaghan, P
    Rademark, C
    Eriksson, R
    Olsson, R
    Hagberg, G
    Nelson, CE
    EUROPEAN UROLOGY, 2000, 37 : 26 - 30
  • [8] INTRAVESICAL BCG OR EPIRUBICIN PROPHYLAXIS IN SUPERFICIAL BLADDER-CANCER
    MELEKOS, MD
    CANCER JOURNAL - FRANCE, 1995, 8 (03): : 124 - 129
  • [9] SYSTEMIC COMPLICATIONS OF INTRAVESICAL BCG THERAPY FOR BLADDER-CANCER
    STEG, A
    SICARD, D
    LELEU, C
    DEBRE, B
    BOCCONGIBOD, L
    LANCET, 1985, 2 (8460): : 899 - 899
  • [10] CLINICAL-VALUE OF PATHOLOGICAL-CHANGES AFTER INTRAVESICAL BCG THERAPY OF SUPERFICIAL BLADDER-CANCER
    BASSI, P
    MILANI, C
    MENEGHINI, A
    GARBEGLIO, A
    ARAGONA, F
    ZATTONI, F
    PALMA, PD
    REBUFFI, A
    PAGANO, F
    UROLOGY, 1992, 40 (02) : 175 - 179